Actualités et Activités de Pfizer Neuroscience & Pain

Derniers communiqués de presse par Pfizer Neuroscience & Pain

• Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union | Pfizer
• Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences | Pfizer
• Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older | Pfizer
• Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine | Pfizer
• Pfizer Announces Positive Top-Line Data from Phase 3 Trial of Older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate | Pfizer
• Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age | Pfizer
• Hospira Issues A Voluntary Nationwide Recall For One Lot of Propofol Injectable Emulsion (containing benzyl alcohol), Due To The Potential Presence of Visible Particulates | Pfizer
• When AI Meets Biology | Pfizer
• Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine | Pfizer
• Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference | Pfizer
• Voir plus de communiqués de presse Close

Réseaux sociaux à propos de Pfizer Neuroscience & Pain

• Pfizer Neuroscience & Pain sur Wikipédia, Google News & Yahoo Finance en 1-click
• Pfizer Neuroscience & Pain sur LinkedIn, Twitter & YouTube en 1-click